Application of insulin-like growth factor-1 in the treatment of inner ear disorders. | Canada Hyperbarics Skip to main content
RCT Frontiers in pharmacology 2014

Application of insulin-like growth factor-1 in the treatment of inner ear disorders.

Yamamoto N, Nakagawa T, Ito J — Frontiers in pharmacology, 2014

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers investigated the application of insulin-like growth factor-1 (IGF-1) for treating sensorineural hearing loss (SNHL) by studying its effects on hair and supporting cells in the inner ear.

What They Found

Researchers found that insulin-like growth factor-1 (IGF-1) treatment maintained hair cell numbers in the postnatal mammalian cochlea following injury, activating two major downstream signaling pathways. In mouse cochlear explants, IGF-1 promoted cell-cycle progression in supporting cells and inhibited hair cell apoptosis, with Netrin1 and Gap43 identified as candidate effector molecules.

Canadian Relevance

This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or participants.

Study Limitations

A key limitation is that much of the research was conducted in preclinical models, meaning further human clinical trials are necessary to confirm the efficacy and safety of IGF-1 in patients.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type RCT
Category Sudden Hearing Loss
Source Pubmed
PubMed ID 25309440
Year Published 2014
Journal Frontiers in pharmacology

Cite This Study

Share

This study relates to Sudden Sensorineural Hearing Loss. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Sudden Hearing Loss

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: April 2, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology